Sunosi (Solriamfetol) for Narcolepsy and OSA: Efficacy, Dosing, and Safety

Sunosi (Solriamfetol): Wake-Promoting Agent for Narcolepsy & OSA

Sunosi is FDA-approved to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA).

How It Works

Sunosi inhibits dopamine and norepinephrine reuptake (DNRI), increasing synaptic concentrations of these arousal-promoting neurotransmitters. Unlike traditional stimulants, it has low affinity for other receptors, potentially reducing abuse potential.

Dosing Guidelines

• Starting dose: 75 mg once daily in the morning.
• Titration: May increase to 150 mg after ≥3 days if needed.
• Maximum: 150 mg/day for narcolepsy; 150 mg/day for OSA (300 mg not approved).
• Take with or without food; avoid afternoon dosing to prevent insomnia.

Common Side Effects (≥5%)

• Headache
• Nausea
• Decreased appetite
• Anxiety
• Insomnia (if taken too late)

Usually mild and transient.

Warnings & Precautions

• Cardiovascular: Monitor blood pressure and heart rate; caution in uncontrolled hypertension, recent MI, or arrhythmias.
• Psychiatric: May exacerbate anxiety, mania, or psychosis; assess history.
• Abuse potential: Schedule IV controlled substance; evaluate for substance misuse history.
• Pregnancy/lactation: Limited data; use only if benefit outweighs risk.

Drug Interactions

• Avoid MAO inhibitors (hypertensive crisis risk).
• Caution with other dopaminergic drugs, pressor agents.
• No significant CYP450 interactions.

Practical Tips for Patients

• Take exactly as prescribed; morning only.
• Track sleepiness with Epworth Sleepiness Scale.
• Combine with CPAP (for OSA) and behavioral strategies (scheduled naps, sleep hygiene).
• Report chest pain, palpitations, mood changes, or insomnia.

Bottom Line

Sunosi is an effective, once-daily option for EDS in narcolepsy/OSA with a distinct mechanism. It requires cardiovascular monitoring and isn't a substitute for treating the underlying sleep disorder (e.g., CPAP for OSA).